Radical irradiation and misonidazole in the treatment of T2 grade III and T3 bladder cancer
Autor: | R.D. Tucker, M.B. Johnson, D.R. Barnes, J.S. Cridland, R. Sealy, R.P. Abratt, M.A. Williams, J.A.S. Green |
---|---|
Rok vydání: | 1983 |
Předmět: |
Male
Radiation-Sensitizing Agents Cancer Research Misonidazole Nausea Administration Oral Pilot Projects chemistry.chemical_compound Carcinoma medicine Humans Radiology Nuclear Medicine and imaging Complete response Aged Radiation Bladder cancer medicine.diagnostic_test business.industry Retrospective cohort study Cystoscopy Middle Aged medicine.disease Urinary Bladder Neoplasms Oncology chemistry Nitroimidazoles Toxicity Female medicine.symptom Nuclear medicine business |
Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 9:629-632 |
ISSN: | 0360-3016 |
Popis: | The results of 2 pilot studies using a new radiation fractionation schedule plus misaddazole (MISO) is the radical radiotherapy of T2 Grade III and T3 carcinoma of the bladder are presented. Forty Gy in 20 daily fractions of 2 Gy was administered to the whole pelvis over 4 weeks followed by 12 Gy in 2 weekly fractions of 6 Gy. These last 2 doses were given after MISO administration. In an initial pilot study (Pilot Study 1) MISO was administered orally only. The first two patients received MISO at a dose of 4.5g/m 3 orally with each radiation fraction, after which the dose was reduced to 3.0g/m 2 because of drug toxicity. In the second pilot study (Pilot Study II) MISO was administered orally at a dose of 3.0g/M 2 and intravesicaily at a dose of I.Og to 22 patients. The complete response rate at cystoscopy at 6 months in the latter group of patients is 73%, which is significantly better than that of 43% obtained in a retrospective study of historical controls. There have been no late radiation complications in any of the patients nor any MISO toxicity apart from nausea in the patients receiving 3.0g/m2 orally with or without the intravesicai MISO. |
Databáze: | OpenAIRE |
Externí odkaz: |